Mirum Pharmaceuticals, Inc.
brelovitug
chronic hepatitis delta virus (HDV)
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for brelovitug in chronic hepatitis delta virus (HDV) are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“topline data from AZURE-1 and AZURE-4 expected in H2 2026.”